Tumor Biology

, Volume 37, Issue 8, pp 11057–11063 | Cite as

Roles of microRNA-124a and microRNA-30d in breast cancer patients with type 2 diabetes mellitus

  • Shu Zhang
  • Ling-Ji Guo
  • Gang Zhang
  • Ling-Li Wang
  • Shuai Hao
  • Bo Gao
  • Yan Jiang
  • Wu-Guo Tian
  • Xian-E Cao
  • Dong-Lin Luo
Original Article


The aim of the study is to explore roles of microRNA (miR)-124a and miR-30d in breast cancer (BC) patients with type 2 diabetes mellitus (T2DM). A total of 144 cases of confirmed diagnosed BC with T2DM, T2DM, BC, or healthy people were enrolled. Among them, BC patients with T2DM were regarded as the experiment group (n = 36), patients with T2DM as the Dm group (n = 36), patients with BC as the Bc group (n = 36), and healthy subjects as the healthy group (n = 36). The fasting insulin resistance index, glycosylated hemoglobin, and estradiol were measured. MiR-124a and miR-30d expressions were detected by quantitative real-time polymerase chain reaction (qRT-PCR). The insulin resistance index was significantly higher in the experiment group compared to the other three groups (all P < 0.05). The glycated hemoglobin was in a normal range in the Bc group and healthy group, but was higher in the experiment group and the Bc group compared to that in the healthy group (both P < 0.05). The serum estradiol level was obviously higher in the Bc group compared with that in the Dm group and the experiment group (both P < 0.05). The expressions of miR-124a and miR-30d were positively correlated with insulin resistance index, BMI and glycosylated hemoglobin (miR-124a r = 0.659, r = 0.785, and r = 0.862; miR-30d r = 0.742, r = 0.805, r = 0.765; all P < 0.001). Insulin resistance index was an independent factor for expressions of miR124-a and miR-30d. MiR-124a and miR-30d were correlated with insulin resistance and development of BC with T2DM. Although the mechanism is not clear, miR-124a and miR-30d potentially may be used as therapeutic targets and prognostic markers for BC patients with T2DM.


MiR-124a MiR-30d Type 2 diabetes mellitus Breast cancer Insulin resistance index Glycosylated hemoglobin Estradiol 



The project was supported by the national science and technology project (2013GS500101-05). We would like to give our sincere appreciation to the reviewers for their helpful comments on this article.

Compliance with ethical standards

All patients signed informed consents. The experiment was approved by the ethics committee of our hospital, and the ethical approval for this study conformed to the standards of the Declaration of Helsinki.

Conflicts of interest



  1. 1.
    Wang RJ, Lu LJ, Jin LB, Li HY, Ren GS, Wu KN, et al. Clinicopathologic features of breast cancer patients with type 2 diabetes mellitus in southwest of china. Med Oncol. 2014;31(1):788.CrossRefPubMedGoogle Scholar
  2. 2.
    Pan B, Ren H, Ma Y, Liu D, Yu B, Ji L, et al. High-density lipoprotein of patients with type 2 diabetes mellitus elevates the capability of promoting migration and invasion of breast cancer cells. Int J Cancer. 2012;131(1):70–82.CrossRefPubMedGoogle Scholar
  3. 3.
    Liu X, Hemminki K, Forsti A, Sundquist K, Sundquist J, Ji J. Cancer risk in patients with type 2 diabetes mellitus and their relatives. Int J Cancer. 2015;137(4):903–10.CrossRefPubMedGoogle Scholar
  4. 4.
    Luo J, Virnig B, Hendryx M, Wen S, Chelebowski R, Chen C, et al. Diabetes, diabetes treatment and breast cancer prognosis. Breast Cancer Res Treat. 2014;148(1):153–62.CrossRefPubMedPubMedCentralGoogle Scholar
  5. 5.
    Kaplan MA, Pekkolay Z, Kucukoner M, Inal A, Urakci Z, Ertugrul H, et al. Type 2 diabetes mellitus and prognosis in early stage breast cancer women. Med Oncol. 2012;29(3):1576–80.CrossRefPubMedGoogle Scholar
  6. 6.
    He DE, Bai JW, Liu J, Du CW, Huang WH, Zhang GJ. Clinicopathological characteristics and prognosis of breast cancer patients with type 2 diabetes mellitus. Mol Clin Oncol. 2015;3(3):607–12.PubMedPubMedCentralGoogle Scholar
  7. 7.
    Li X, Du N, Zhang Q, Li J, Chen X, Liu X, et al. MicroRNA-30d regulates cardiomyocyte pyroptosis by directly targeting foxo3a in diabetic cardiomyopathy. Cell Death Dis. 2014;5:e1479.CrossRefPubMedPubMedCentralGoogle Scholar
  8. 8.
    Trehoux S, Lahdaoui F, Delpu Y, Renaud F, Leteurtre E, Torrisani J, et al. Micro-RNAs miR-29a and miR-330-5p function as tumor suppressors by targeting the MUC1 mucin in pancreatic cancer cells. Biochim Biophys Acta. 2015;1853(10):2392–403.CrossRefPubMedGoogle Scholar
  9. 9.
    Li J, Li L, Li Z, Gong G, Chen P, Liu H, et al. The role of miR-205 in the VEGF-mediated promotion of human ovarian cancer cell invasion. Gynecol Oncol. 2015;137(1):125–33.CrossRefPubMedGoogle Scholar
  10. 10.
    Kim S, Rhee JK, Yoo HJ, Lee HJ, Lee EJ, Lee JW, et al. Bioinformatic and metabolomic analysis reveals miR-155 regulates thiamine level in breast cancer. Cancer Lett. 2015;357(2):488–97.CrossRefPubMedGoogle Scholar
  11. 11.
    Chen X, He D, Dong XD, Dong F, Wang J, Wang L, et al. MicroRNA-124a is epigenetically regulated and acts as a tumor suppressor by controlling multiple targets in uveal melanoma. Invest Ophthalmol Vis Sci. 2013;54(3):2248–56.CrossRefPubMedGoogle Scholar
  12. 12.
    Sebastiani G, Po A, Miele E, Ventriglia G, Ceccarelli E, Bugliani M, et al. MicroRNA-124a is hyperexpressed in type 2 diabetic human pancreatic islets and negatively regulates insulin secretion. Acta Diabetol. 2015;52(3):523–30.CrossRefPubMedGoogle Scholar
  13. 13.
    Yu H, Lin X, Wang F, Zhang B, Wang W, Shi H, et al. Proliferation inhibition and the underlying molecular mechanisms of microRNA-30d in renal carcinoma cells. Oncol Lett. 2014;7(3):799–804.PubMedGoogle Scholar
  14. 14.
    Zhao X, Mohan R, Ozcan S, Tang X. MicroRNA-30d induces insulin transcription factor mafa and insulin production by targeting mitogen-activated protein 4 kinase 4 (map4k4) in pancreatic beta-cells. J Biol Chem. 2012;287(37):31155–64.CrossRefPubMedPubMedCentralGoogle Scholar
  15. 15.
    PN M. World medical association publishes the revised Declaration of Helsinki. Natl Med J India. 2014;27(1):56.Google Scholar
  16. 16.
    Lou M, Luo P, Tang R, Peng Y, Yu S, Huang W, et al. Relationship between neutrophil-lymphocyte ratio and insulin resistance in newly diagnosed type 2 diabetes mellitus patients. BMC Endocr Disord. 2015;15:9.CrossRefPubMedPubMedCentralGoogle Scholar
  17. 17.
    Pala L, Barbaro V, Dicembrini I, Rotella CM. The therapy of insulin resistance in other diseases besides type 2 diabetes. Eat Weight Disord. 2014;19(3):275–83.CrossRefPubMedPubMedCentralGoogle Scholar
  18. 18.
    Okuno A, Kaji N, Takahashi A, Nagakubo D, Ohno-Ichiki K, Shirai M, et al. Role of insulin resistance in the pathogenesis and development of type 2 diabetes in wbn/kob-lepr(fa) rats. J Vet Med Sci. 2013;75(12):1557–61.CrossRefPubMedPubMedCentralGoogle Scholar
  19. 19.
    Mizokami-Stout K, Cree-Green M, Nadeau KJ. Insulin resistance in type 2 diabetic youth. Curr Opin Endocrinol Diabetes Obes. 2012;19(4):255–62.CrossRefPubMedPubMedCentralGoogle Scholar
  20. 20.
    Liu A, Kushida CA, Reaven GM. Habitual shortened sleep and insulin resistance: an independent relationship in obese individuals. Metabolism. 2013;62(11):1553–6.CrossRefPubMedGoogle Scholar
  21. 21.
    Yoon SR, Lee JH, Na GY, Seo YJ, Han S, Shin MJ, et al. Glycated hemoglobin is a better predictor than fasting glucose for cardiometabolic risk in non-diabetic Korean women. Clin Nutr Res. 2015;4(2):97–103.CrossRefPubMedPubMedCentralGoogle Scholar
  22. 22.
    Incani M, Sentinelli F, Perra L, Pani MG, Porcu M, Lenzi A, et al. Glycated hemoglobin for the diagnosis of diabetes and prediabetes: diagnostic impact on obese and lean subjects, and phenotypic characterization. J Diabetes Investig. 2015;6(1):44–50.CrossRefPubMedGoogle Scholar
  23. 23.
    Joshu CE, Prizment AE, Dluzniewski PJ, Menke A, Folsom AR, Coresh J, et al. Glycated hemoglobin and cancer incidence and mortality in the Atherosclerosis in Communities (ARIC) study, 1990–2006. Int J Cancer. 2012;131(7):1667–77.CrossRefPubMedPubMedCentralGoogle Scholar
  24. 24.
    Li XL, Li JJ, Guo YL, Zhu CG, Xu RX, Li S, et al. Relationship of glycated hemoglobin levels with myocardial injury following elective percutaneous coronary intervention in patients with type 2 diabetes mellitus. PLoS One. 2014;9(7), e101719.CrossRefPubMedPubMedCentralGoogle Scholar
  25. 25.
    Su HI, Sue LY, Flatt SW, Natarajan L, Patterson RE, Pierce JP. Endogenous estradiol is not associated with poor physical health in postmenopausal breast cancer survivors. J Womens Health (Larchmt). 2013;22(12):1043–8.CrossRefGoogle Scholar
  26. 26.
    Kim JY, Han W, Moon HG, Ahn SK, Kim J, Lee JW, et al. Prognostic effect of preoperative serum estradiol level in postmenopausal breast cancer. BMC Cancer. 2013;13:503.CrossRefPubMedPubMedCentralGoogle Scholar
  27. 27.
    Chalasani P, Stopeck A, Clarke K, Livingston R. A pilot study of estradiol followed by exemestane for reversing endocrine resistance in postmenopausal women with hormone receptor-positive metastatic breast cancer. Oncologist. 2014;19(11):1127–8.CrossRefPubMedPubMedCentralGoogle Scholar
  28. 28.
    Ben Gacem R, Ben Abdelkrim O, Ziadi S, Ben Dhiab M, Trimeche M. Methylation of miR-124a-1, miR-124a-2, and miR-124a-3 genes correlates with aggressive and advanced breast cancer disease. Tumour Biol. 2014;35(5):4047–56.CrossRefPubMedGoogle Scholar
  29. 29.
    Kobayashi N, Uemura H, Nagahama K, Okudela K, Furuya M, Ino Y, et al. Identification of miR-30d as a novel prognostic maker of prostate cancer. Oncotarget. 2012;3(11):1455–71.CrossRefPubMedPubMedCentralGoogle Scholar
  30. 30.
    Ling HY, Hu B, Hu XB, Zhong J, Feng SD, Qin L, et al. MiRNA-21 reverses high glucose and high insulin induced insulin resistance in 3t3-l1 adipocytes through targeting phosphatase and tensin homologue. Exp Clin Endocrinol Diabetes. 2012;120(9):553–9.CrossRefPubMedGoogle Scholar
  31. 31.
    Mao Q, Unadkat JD. Role of the breast cancer resistance protein (bcrp/abcg2) in drug transport—an update. AAPS J. 2015;17(1):65–82.CrossRefPubMedGoogle Scholar

Copyright information

© International Society of Oncology and BioMarkers (ISOBM) 2016

Authors and Affiliations

  • Shu Zhang
    • 1
  • Ling-Ji Guo
    • 1
  • Gang Zhang
    • 1
  • Ling-Li Wang
    • 1
  • Shuai Hao
    • 1
  • Bo Gao
    • 1
  • Yan Jiang
    • 1
  • Wu-Guo Tian
    • 1
  • Xian-E Cao
    • 1
  • Dong-Lin Luo
    • 1
  1. 1.Department of Breast, Thyroid, and Vascular Surgery, Research Institute of Surgery, Daping HospitalThird Military Medical UniversityYuzhong AreaChina

Personalised recommendations